# US 2020/0206190 A1 · Compositions and methods for treating neoplastic diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206190 A1
- Document ID: US20200206190A1
- Status: Published application
- Kind: A1
- Application number: 16/800,570
- Filed: 2020-02-25
- Published: 2020-07-02
- Earliest claimed: 2004-12-03
- Assignees: Celgene International II SÀRL; Dana-Farber Cancer Institute, Inc.
- Applicants: Celgene International II Sàrl; Dana-Farber Cancer Institute, Inc.
- Inventors: Kenneth C. ANDERSON; Dharminder CHAUHAN; Michael A. PALLADINO
- Web page: https://patentgrep.com/patent/US20200206190A1

## CPC

- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/69: Boron compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for treating neoplastic diseases. Included are compositions and methods that are effective against multiple myeloma cells resistant to conventional and bortezomib treatment. Furthermore, combination treatment with two different proteosome inhibitors is shown to be synergistic for treating multiple myeloma.

## Claims

### Claim 1

A method of treating a neoplastic disease, comprising:
administering to a patient inflicted with the neoplastic disease a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine, and
wherein the neoplastic disease is susceptible to resistance to at least one other chemotherapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein X is chlorine.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound of formula (I) has the structure of formula (II):

### Claim 4 (depends on 1)

The method of claim 1, wherein the neoplastic disease is cancer.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cancer is selected from the group consisting of breast cancer, sarcoma, leukemia, ovarian cancer, uretal cancer, bladder cancer, prostate cancer, colon cancer, rectal cancer, stomach cancer, lung cancer, lymphoma, multiple myeloma, pancreatic cancer, liver cancer, kidney cancer, endocrine cancer, skin cancer, melanoma, angioma, and brain or central nervous system (CNS) cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is selected from the group consisting of multiple myeloma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, non-small cell lung carcinoma, and an ovarian carcinoma or melanoma.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is a multiple myeloma.

### Claim 8 (depends on 1)

The method of claim 1, wherein the patient is a human.

### Claim 9 (depends on 1)

The method of claim 1, wherein the other chemotherapeutic agent is selected from the group consisting of dexamethasone, doxorubicin, and thalidomide.

### Claim 10 (depends on 1)

The method of claim 1, wherein the other chemotherapeutic agent is a proteosome inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the other chemotherapeutic agent is bortezomib.

### Claim 12

A method of treating a neoplastic disease, comprising administering to a patient inflicted with the neoplastic disease a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine, in combination with at least one additional chemotherapeutic agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein X is chlorine.

### Claim 14 (depends on 12)

The method of claim 12, wherein the compound of formula (I) has the structure of formula (II):

### Claim 15 (depends on 12)

The method of claim 12, wherein the neoplastic disease is cancer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the cancer is selected from the group consisting of breast cancer, sarcoma, leukemia, ovarian cancer, uretal cancer, bladder cancer, prostate cancer, colon cancer, rectal cancer, stomach cancer, lung cancer, lymphoma, multiple myeloma, pancreatic cancer, liver cancer, kidney cancer, endocrine cancer, skin cancer, melanoma, angioma, and brain or central nervous system (CNS) cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is selected from the group consisting of multiple myeloma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, non-small cell lung carcinoma, and an ovarian carcinoma or melanoma.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cancer is a multiple myeloma.

### Claim 19 (depends on 12)

The method of claim 12, wherein the patient is a human.

### Claim 20 (depends on 12)

The method of claim 12, wherein the other chemotherapeutic agent is selected from the group consisting of dexamethasone, doxorubicin, and thalidomide.

### Claim 21 (depends on 12)

The method of claim 12, wherein the other chemotherapeutic agent is a proteosome inhibitor.

### Claim 22 (depends on 21)

The method of claim 21, wherein the other chemotherapeutic agent is bortezomib.

### Claim 23 (depends on 12)

The method of claim 12, wherein the combination is synergistic.

### Claim 24 (depends on 12)

The method of claim 12, wherein the combination is additive.

### Claim 25

A pharmaceutical composition, comprising:
a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine; and
at least one additional chemotherapeutic agent.

### Claim 26 (depends on 25)

The composition of claim 25, wherein X is chlorine.

### Claim 27 (depends on 25)

The composition of claim 25, wherein the compound of formula (I) has the structure of formula (II):

### Claim 28 (depends on 25)

The composition of claim 25, wherein the other chemotherapeutic agent is selected from the group consisting of dexamethasone, doxorubicin, and thalidomide.

### Claim 29 (depends on 25)

The composition of claim 25, wherein the other chemotherapeutic agent is a proteosome inhibitor.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the other chemotherapeutic agent is bortezomib.

### Claim 31

A method of treating a neoplastic disease, comprising administering to a patient inflicted with the neoplastic disease a synergistic combination of at least two proteosome inhibitors.

### Claim 32 (depends on 31)

The method of claim 31, wherein the neoplastic disease is cancer.

### Claim 33 (depends on 32)

The method of claim 32, wherein the cancer is selected from the group consisting of breast cancer, sarcoma, leukemia, ovarian cancer, uretal cancer, bladder cancer, prostate cancer, colon cancer, rectal cancer, stomach cancer, lung cancer, lymphoma, multiple myeloma, pancreatic cancer, liver cancer, kidney cancer, endocrine cancer, skin cancer, melanoma, angioma, and brain or central nervous system (CNS) cancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the cancer is selected from the group consisting of multiple myeloma, colorectal carcinoma, prostate carcinoma, breast adenocarcinoma, non-small cell lung carcinoma, and an ovarian carcinoma or melanoma.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cancer is a multiple myeloma.

### Claim 36 (depends on 31)

The method of claim 31, wherein the patient is a human.

### Claim 37 (depends on 31)

The method of claim 31, wherein at least one of the proteosome inhibitors is selected from the group consisting of bortezomib and the compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof:
wherein X is selected from the group consisting of fluorine, chlorine, bromine or iodine.
